Key facts
- This page summarizes Quintin J. Lai's Form 4 filing for WEST PHARMACEUTICAL SERVICES INC (WST).
- 13 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 15 Aug 2023, 14:50.
Quintin J. Lai - 11 Aug 2023 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)
- Reporting relationship
- VP Strat & Investor Relations
- Issuer ticker
- WST
- Reported as of
- 11 Aug 2023
- Net transaction value
- -$5,691,372
- SEC form
- 4
- Accepted by SEC
- 15 Aug 2023, 14:50:41 UTC
- Prior SEC filing
- 23 Feb 2023
- Next SEC filing
- 22 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- Ryan Metz as Agent for Quintin J. Lai
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Quintin J. Lai filed Form 4 for WEST PHARMACEUTICAL SERVICES INC (WST) on 15 Aug 2023.
Change
- Previous filing in this sequence was filed on 23 Feb 2023.
- Current net transaction value: -$5,691,372.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WST
transaction
Common Stock
Options Exercise
- Transaction value
- $786,322
- Shares
- +8,772
- Change %
- +48%
- Price
- $89.64*
- Shares after
- 27,079
- Date
- 11 Aug 2023
- Ownership
- Direct
WST
transaction
Common Stock
Options Exercise
- Transaction value
- $731,921
- Shares
- +7,140
- Change %
- +26%
- Price
- $102.51
- Shares after
- 34,219
- Date
- 11 Aug 2023
- Ownership
- Direct
WST
transaction
Common Stock
Options Exercise
- Transaction value
- $579,941
- Shares
- +3,348
- Change %
- +9.8%
- Price
- $173.22
- Shares after
- 37,567
- Date
- 11 Aug 2023
- Ownership
- Direct
WST
transaction
Common Stock
Options Exercise
- Transaction value
- $380,715
- Shares
- +1,388
- Change %
- +3.7%
- Price
- $274.29
- Shares after
- 38,955
- Date
- 11 Aug 2023
- Ownership
- Direct
WST
transaction
Common Stock
Options Exercise
- Transaction value
- $167,216
- Shares
- +453
- Change %
- +1.2%
- Price
- $369.13
- Shares after
- 39,408
- Date
- 11 Aug 2023
- Ownership
- Direct
WST
transaction
Common Stock
Sale
- Transaction value
- $4,232,326
- Shares
- -10,725
- Change %
- -27%
- Price
- $394.62
- Shares after
- 28,683
- Date
- 11 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
WST
transaction
Common Stock
Sale
- Transaction value
- $3,415,510
- Shares
- -8,635
- Change %
- -30%
- Price
- $395.54
- Shares after
- 20,048
- Date
- 11 Aug 2023
- Ownership
- Direct
- Footnotes
- F2
WST
transaction
Common Stock
Sale
- Transaction value
- $689,650
- Shares
- -1,741
- Change %
- -8.7%
- Price
- $396.12
- Shares after
- 18,307
- Date
- 11 Aug 2023
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
WST
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -8,772
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,772
- Exercise price
- $89.64
- Footnotes
- F4
WST
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -7,140
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,140
- Exercise price
- $102.51
- Footnotes
- F4
WST
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -3,348
- Change %
- -75%
- Price
- $0.000000
- Shares after
- 1,116
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,348
- Exercise price
- $173.22
- Footnotes
- F5
WST
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,388
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 1,388
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,388
- Exercise price
- $274.29
- Footnotes
- F6
WST
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -453
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 1,359
- Date
- 11 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 453
- Exercise price
- $369.13
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $393.97 to $394.96, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Footnote F2
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $394.97 to $395.93, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Footnote F3
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $395.97 to $396.45, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
Footnote F4
This option is fully vested.
Footnote F5
This award vests in four equal annual installments beginning on February 18, 2021.
Footnote F6
This award vests in 4 equal annual installments beginning on 2/23/2022.
Footnote F7
This award vests in four equal annual installments beginning on February 22, 2023.